CURE Pharmaceutical begins 2019 on a high note

We report significant activity this quarter, setting the pace for a strong start to 2019. Clinical planning has commenced for our CUREfilm Blue™ (Sildenafil 50mg) product on the heels of a pre-IND meeting with the FDA in March. We recently announced our planned acquisition of Chemistry Holdings which will bring novel and complementary formulation technology…

Wealth Minerals Management to Host Conference Call

GlobeNewswire•April 4, 2019 Provides Update on Spin-Out of Copper Subsidiary VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN) announces a conference call with management to discuss the Company’s current operations, recently announced news on Atacama and the National Mining…

Wealth Completes US$2M Atacama Payment

Registers Ownership of the Atacama Property Wealth Minerals Ltd.April 02, 2019 10:30 ET Registers Ownership of the Atacama Property VANCOUVER, British Columbia, April 02, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), announces it has completed the US$2 million option payment for the…

CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery

GlobeNewswire•April 1, 2019 OXNARD, Calif., April 01, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has agreed to acquire Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction.…

CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction

GlobeNewswire• March 26, 2019 OXNARD, Calif., March 26, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA). The FDA provided feedback supportive of CURE’s clinical development plans for its CUREfilm…

Wealth Announces Option For 100% Of Meductic Vanadium Property

GlobeNewswire •March 13, 2019 Cancels Incentive Stock Options VANCOUVER, British Columbia, March 13, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), announces that it has signed an option agreement giving it the right (the “Option”) to acquire a 100% interest (subject to a 2% NSR royalty)…

CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

GlobeNewswire•March 12, 2019 OXNARD, Calif., March 12, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE…

Energy Fuels Announces 2018 Results

PR Newswire•March 12, 2019 LAKEWOOD, CO, March 12, 2019 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), today reported its financial results for the year ended December 31, 2018. The Company’s Annual Report on Form 10-K has been filed with the U.S. Securities and Exchange Commission (“SEC”), and may…

Wealth Closes $1.35m Loan

GlobeNewswire•March 6, 2019 VANCOUVER, British Columbia, March 06, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), reports it has closed its loan placement, as announced on February 11, 2019, to third-party lenders as well as an insider. The total loan sum closed is…